Erratum: Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy (Bone Marrow Transplantation (2008) vol. 42 (253-257) 10.1038/bmt.2008.160);Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy

Bone Marrow Transplantation

Volumn 42, Issue 4, 2008, Pages 253-257

  Bonnanomi, S ^a   Connor, P ^a   Webb, D ^a   Ancliff, P ^a   Amrolia, P ^a   Rao, K ^a   McCloskey, D ^b   Hemmatpour, S ^b   Goulden, N ^a   Veys, P ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIBIOTIC AGENT; ASPARAGINASE; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SIBLING; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS INFECTION;

EID: 51049093177     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.342     Document Type: Erratum

References (24)

1. Gibson BES, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK et al. Treatment strategy and long term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
2. Gibson B, Hann I, Webb D, De Graaf S, Stevens R, Hills R et al. Should stem cell transplantation be recommended for any child with AML in 1st CR? (abstract). Blood 2005; 106: 171a.
3. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 2007; 136: 229-236.
4. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109: 157-163.
5. Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 2005; 36: 83-91.
6. Woodard P, Barfield k, Hale G, Horwitz E, Leung W, Ribeiro R et al. Outcome of hematopoictic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006; 47: 931-935.
7. Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Exp Haematol 2003; 31: 1182-1186.
8. Locatelli F, Zecca M, Niemeyer C, Angelucci E, Arcese G, Bender-Gotze C et al. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria-Germany-Italy (AGI) Bone Marrow Transplantation Registry. Bone Marrow Transplant 996; 18 (suppl 2): 63-68.
9. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C et al. European Working Group on Childhood MDS; European Blood and Marrow Transplantation Group. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419.
10. Giorgiani G, Bozzola M, Locatelli F, Picco P, Zecca M, Cisternio M et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995; 86: 825-831.
11. Couto-Silva AC, Trivin C, Esperou H, Michon J, Baruchel A, Lemaire P et al. Final height and good function after total body irradiation during childhood. Bone Marrow Transplant 2006; 38: 427-432.
12. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Picco JL, Bordigoni P et al. All Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation - a report from the Société Française de Greffe de Moelle. J Clin Oncol 1994; 12: 1217-1222.
13. Parth P, Dunlap WP, Kennedy RS, Ordy JM, Lane NE. Motor and cognitive testing of bone marrow transplant patients after chemoradiotherapy. Percept Mot Skills 1989; 68: 1227-1241.
14. Locatelli F, Labopin M, Ortega J, Meloni G, Dini G, Messina C et al. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 2003; 101 1611-1619.
15. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004; 33: 815-821.
16. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D et al. improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-885.
17. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestatiori of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
18. Sandler ES, Hagg R, Coppers MJ, Mustaffa MM, Gamis A, Kamani N et al. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the Pediatric Blood and Marrow Transplant Consortium. Med Pediatr Oncol 2000; 35 403-409.
19. Ayas M, Al-Seraihi A, Al-Mahr M, Al-Jefri A, Belgaumi A, Elhassan I et al. The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen. Pediatr Blood Cancer 2006; 47: 926-930.
20. Chown SR, Marks DI, Cornish JM, Pamphilon DH, Potter MN, Steward CG et al. Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. Br J Haematol 1997; 99: 36-40.
21. Neudorf S, Sanders J, Kobrinsky N, Alonso TA, Buxton AB, Gold S et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004; 103: 3655-3661.
22. Abrham R, Szer J, Bardy P, Grigg A. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant 1997; 20: 773-777.
23. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007; 110: 409-417.
24. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukaemia in remission: A report from the Children's Cancer Group. Blood 2001; 97: 56-62.